BR112016021034A8 - pharmaceutical composition, use thereof and kit - Google Patents

pharmaceutical composition, use thereof and kit

Info

Publication number
BR112016021034A8
BR112016021034A8 BR112016021034A BR112016021034A BR112016021034A8 BR 112016021034 A8 BR112016021034 A8 BR 112016021034A8 BR 112016021034 A BR112016021034 A BR 112016021034A BR 112016021034 A BR112016021034 A BR 112016021034A BR 112016021034 A8 BR112016021034 A8 BR 112016021034A8
Authority
BR
Brazil
Prior art keywords
disease
kit
pharmaceutical composition
carbidopa
antioxidant
Prior art date
Application number
BR112016021034A
Other languages
Portuguese (pt)
Other versions
BR112016021034A2 (en
Inventor
Yacoby-Zeevi Oron
Original Assignee
Neuroderm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuroderm Ltd filed Critical Neuroderm Ltd
Publication of BR112016021034A2 publication Critical patent/BR112016021034A2/en
Publication of BR112016021034A8 publication Critical patent/BR112016021034A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Abstract

composição farmacêutica, uso de tal composição, método para tratar uma doença e kit a presente invenção provê composições farmacêuticas altamente estáveis baseadas em carbidopa compreendendo uma combinação de antioxidante consistindo em ácido ascórbico e pelo menos um antioxidante adicional em que dita combinação inibe fortemente a degradação de carbidopa. estas composições podem adicionalmente compreender levodopa e/ou um ou ambos arginina e meglumina, e são benéficos no tratamento de uma doença, distúrbio ou condição associada com perda de dopamina ou neurônios dopaminérgicos, por exemplo, doença de parkinson.pharmaceutical composition, use of such composition, method to treat a disease and kit the present invention provides highly stable pharmaceutical compositions based on carbidopa comprising an antioxidant combination consisting of ascorbic acid and at least one additional antioxidant wherein said combination strongly inhibits the degradation of carbidopa. these compositions may further comprise levodopa and/or one or both of arginine and meglumine, and are beneficial in the treatment of a disease, disorder or condition associated with loss of dopamine or dopaminergic neurons, e.g. Parkinson's disease.

BR112016021034A 2014-03-13 2015-03-12 pharmaceutical composition, use thereof and kit BR112016021034A8 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461952477P 2014-03-13 2014-03-13
US201461990967P 2014-05-09 2014-05-09
PCT/IL2015/050258 WO2015136538A1 (en) 2014-03-13 2015-03-12 Dopa decarboxylase inhibitor compositions

Publications (2)

Publication Number Publication Date
BR112016021034A2 BR112016021034A2 (en) 2017-08-15
BR112016021034A8 true BR112016021034A8 (en) 2021-06-29

Family

ID=53488380

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016021034A BR112016021034A8 (en) 2014-03-13 2015-03-12 pharmaceutical composition, use thereof and kit

Country Status (19)

Country Link
US (4) US10022320B2 (en)
EP (3) EP3777833B1 (en)
JP (2) JP6591995B2 (en)
CN (1) CN106413754B (en)
AU (1) AU2015228369B2 (en)
BR (1) BR112016021034A8 (en)
CA (1) CA2942244C (en)
DK (2) DK3116475T3 (en)
ES (2) ES2967693T3 (en)
FI (1) FI3777833T3 (en)
HR (2) HRP20231716T1 (en)
HU (2) HUE052642T2 (en)
IL (1) IL247668B (en)
MX (1) MX2016011837A (en)
PL (2) PL3777833T3 (en)
PT (2) PT3116475T (en)
RS (1) RS65060B1 (en)
RU (1) RU2684105C2 (en)
WO (1) WO2015136538A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3192500T (en) 2009-05-19 2021-01-05 Neuroderm Ltd Compositions for continuous administration of dopa decarboxylase inhibitors
SG10201509316SA (en) 2010-11-15 2015-12-30 Neuroderm Ltd Continuous Administration Of L-Dopa, Dopa Decarboxylase Inhibitors, Catechol-O-Methyl Transferase Inhibitors And Compositions For Same
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
ES2967693T3 (en) 2014-03-13 2024-05-03 Neuroderm Ltd Dopa decarboxylase inhibitor compositions
CA2997791A1 (en) 2015-09-30 2017-04-06 Duke University Ascorbate formulations and methods of use as contrast agents
WO2018154447A1 (en) * 2017-02-21 2018-08-30 Neuroderm Ltd Dopa decarboxylase inhibitor compositions
SG11202104499RA (en) 2018-11-15 2021-05-28 Abbvie Inc Pharmaceutical formulations for subcutaneous administration
WO2020178810A1 (en) * 2019-03-04 2020-09-10 Neuroderm, Ltd. Pharmaceutical compositions comprising levodopa amide derivatives and uses thereof
CN111701024B (en) * 2020-05-26 2022-05-24 上海京新生物医药有限公司 Levodopa preparation and preparation method and application thereof
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
CN113396897B (en) * 2021-07-26 2022-06-07 苏州华测生物技术有限公司 Method for stabilizing carbidopa/levodopa in biological matrix

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3769424A (en) 1970-10-01 1973-10-30 Merck & Co Inc Composition and method of treating dopamine deficiency in brain tissue
AU6889274A (en) 1973-05-17 1975-11-20 Astra Laekemedel Ab Treatment of neurological disorders
US3936495A (en) 1973-11-27 1976-02-03 Merck & Co., Inc. Purification process
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4241082A (en) 1977-09-02 1980-12-23 Sankyo Company Limited Agents for promoting reproductive ability of domestic animals
JPS5450700A (en) 1977-09-28 1979-04-20 Sankyo Co Glazing agent of animal leather
JPS6021570B2 (en) 1978-07-04 1985-05-28 三共株式会社 Method for manufacturing high concentration preparations of DOPAs
JPS56115749A (en) 1980-02-18 1981-09-11 Sagami Chem Res Center Dopa derivative
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4642316A (en) 1985-05-20 1987-02-10 Warner-Lambert Company Parenteral phenytoin preparations
ATE76747T1 (en) 1986-06-10 1992-06-15 Chiesi Farma Spa PHARMACEUTICAL COMPOSITIONS CONTAINING LEVODOPA METHYL ESTER, THEIR PREPARATION AND THERAPEUTIC USES.
US4832957A (en) 1987-12-11 1989-05-23 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
US4684666A (en) 1986-08-19 1987-08-04 Haas Pharmaceuticals, Inc. Stabilized liquid analgesic compositions
IT1226902B (en) 1988-07-12 1991-02-21 Mini Ricerca Scient Tecnolog LEVODOPA SYNTHESIS PROCESS
US4963568A (en) 1989-05-31 1990-10-16 Abbott Laboratories Dopamine agonists
CA2058975C (en) 1990-10-30 2000-06-06 Shuichi Kasai Antiinflammatory gel preparation
US5877176A (en) 1991-12-26 1999-03-02 Cornell Research Foundation, Inc. Blocking induction of tetrahydrobiopterin to block induction of nitric oxide synthesis
CA2143070C (en) 1994-02-22 2001-12-18 Pankaj Modi Oral controlled release liquid suspension pharmaceutical formulation
RU2176145C2 (en) 1995-05-26 2001-11-27 Пфайзер Инк. Synergetic treatment of parkinsonism
GB9523833D0 (en) 1995-11-22 1996-01-24 Boots Co Plc Medical treatment
IL119417A (en) 1996-10-13 2003-02-12 Moshe Kushnir Pharmaceutical composition for transdermal administration of levodopa for parkinson's disease
US6746688B1 (en) 1996-10-13 2004-06-08 Neuroderm Ltd. Apparatus for the transdermal treatment of Parkinson's disease
US5861423A (en) 1997-02-21 1999-01-19 Caldwell; William Scott Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds
WO1999048876A1 (en) 1998-03-20 1999-09-30 Warner-Lambert Company Crystalline sodium phenytoin monohydrate
US7201923B1 (en) 1998-03-23 2007-04-10 General Mills, Inc. Encapsulation of sensitive liquid components into a matrix to obtain discrete shelf-stable particles
PL204921B1 (en) 1998-05-15 2010-02-26 Warner Lambert Co Stabilized pharmaceutical preparations of gamma-aminobutyric acid derivatives and process for preparing the same
US6274168B1 (en) 1999-02-23 2001-08-14 Mylan Pharmaceuticals Inc. Phenytoin sodium pharmaceutical compositions
US6716452B1 (en) 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
AU3490300A (en) 1999-03-12 2000-10-04 Nitromed, Inc. Dopamine agonists in combination with nitric oxide donors, compositions and methods of use
FI109453B (en) 1999-06-30 2002-08-15 Orion Yhtymae Oyj Pharmaceutical composition
US7479498B2 (en) 1999-08-23 2009-01-20 Phoenix Biosciences, Inc. Treatments for viral infections
US6348965B1 (en) 1999-09-24 2002-02-19 Henry Palladino Solid state fluorescence and absorption spectroscopy
SE0001151D0 (en) 2000-03-31 2000-03-31 Amarin Dev Ab Method of producing a controlled-release composition
US20020028799A1 (en) 2000-07-06 2002-03-07 Naylor Alasdair Mark Treatment of male sexual dysfunction
GB0017387D0 (en) 2000-07-14 2000-08-30 Pfizer Ltd Novel enzyme
US20020099013A1 (en) 2000-11-14 2002-07-25 Thomas Piccariello Active agent delivery systems and methods for protecting and administering active agents
US20030119714A1 (en) 2000-12-15 2003-06-26 Naylor Alasdair Mark Treatment of male sexual dysfunction
US20030105090A1 (en) 2000-12-21 2003-06-05 David Bebbington Pyrazole compounds useful as protein kinase inhibitors
IL159812A0 (en) 2001-07-12 2004-06-20 Teva Pharma Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester in a controlled release core
BRPI0213425B8 (en) 2001-10-19 2021-05-25 Idexx Lab Inc injectable compositions for the controlled release of pharmacologically active compound, uses of said compound and method for its preparation
WO2003050261A2 (en) 2001-12-10 2003-06-19 Bristol-Myers Squibb Company (1-phenyl-2-heteroaryl)ethyl-guanidine compounds as inhibitors of mitochondrial f1f0 atp hydrolase
ES2189682B1 (en) 2001-12-11 2004-04-01 Laboratorios Del Dr. Esteve, S.A. DRINKABLE PREPARATION UNDERSTANDING KETOPROPHEN AND ITS EMPLOYMENT IN THE PROCESSING OF PROCESSES PROCESSING WITH FEVER, INFLAMMATION AND / OR PAIN, IN AN ANIMAL COLLECTIVE, SIMULTANEOUSLY.
BR0309113A (en) 2002-04-11 2005-02-01 Ranbaxy Lab Ltd Carbidopa and levodopa controlled release pharmaceutical compositions and processes for their preparation
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
CA2500320A1 (en) 2002-10-10 2004-04-29 Morphochem Aktiengesellschaft Fuer Kombinatorische Chemie Novel compounds with antibacterial activity
WO2004069146A2 (en) 2003-02-07 2004-08-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem L-dopa amide derivatives and uses thereof
EP1646445A4 (en) 2003-07-18 2007-09-19 Baxter Int Methods for fabrication, uses and compositions of small spherical particles prepared by controlled phase separation
US8173840B2 (en) 2003-07-29 2012-05-08 Signature R&D Holdings, Llc Compounds with high therapeutic index
US7589233B2 (en) 2003-07-29 2009-09-15 Signature R&D Holdings, Llc L-Threonine derivatives of high therapeutic index
GB0319935D0 (en) 2003-08-26 2003-09-24 Cipla Ltd Polymorphs
ES2360759T3 (en) * 2003-08-29 2011-06-08 Centocor Ortho Biotech Inc. PHARMACEUTICAL COMPOSITIONS AND PROCEDURE FOR USE OF LEVODOPA AND CARBIDOPA.
US20050070608A1 (en) * 2003-08-29 2005-03-31 Julius Remenar Pharmaceutical compositions and method of using levodopa and carbidopa
US20050053669A1 (en) 2003-09-05 2005-03-10 Boehringer Ingelheim International Gmbh Administration form for the oral application of poorly soluble acidic and amphorteric drugs
AU2004285533A1 (en) 2003-10-31 2005-05-12 Alza Corporation Compositions and dosage forms for enhanced absorption
WO2005099678A1 (en) 2004-04-06 2005-10-27 Transform Pharmaceuticals, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
SE0401842D0 (en) 2004-07-12 2004-07-12 Dizlin Medical Design Ab Infusion and injection solution of levodopa
WO2006029411A2 (en) 2004-09-09 2006-03-16 Yeda Research And Development Co. Ltd. Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof
WO2006037061A2 (en) 2004-09-28 2006-04-06 Farouk Karoum Compositions and methods of using d-dopa to treat parkinson's disease
US20060088607A1 (en) 2004-10-01 2006-04-27 Stefano George B Nutritional supplement compositions
EA013161B1 (en) 2005-06-08 2010-02-26 Орион Корпорейшн An oral dosage form
DE102006021872B4 (en) 2006-05-11 2008-04-17 Sanofi-Aventis 4,5-Diphenyl-pyrimidinyl-oxy or -mercapto substituted carboxylic acids, process for their preparation and their use as medicaments
UA95954C2 (en) 2006-05-31 2011-09-26 Солвей Фармасьютикалс Гмбх Long term 24 hour intestinal administration of levodopa/carbidopa
CL2007002574A1 (en) 2006-09-08 2008-05-23 Drug Tech Corp Sa Organizada B ORAL PHARMACEUTICAL COMPOSITION INCLUDING LEVODOPA IN A UNIT DOSE OF AROUND 100 TO AROUND 500 MG AND AN ADEQUATE EXCIPIENT; AND ITS USE TO TREAT PARKINSON.
CA2606658A1 (en) 2006-10-13 2008-04-13 Mike Tyers Compositions and methods for treating neurological disorders or damage
CA2682888A1 (en) 2007-04-06 2008-10-16 Transform Pharmaceuticals, Inc. Systems and methods for delivering a fluid drug
CL2008003507A1 (en) 2007-11-26 2009-11-27 Neuroderm Ltd Pharmaceutical composition comprising nicotine and a nicotinic acetylcholine receptor (nachr) opipramol desensitization inhibitor; pharmaceutical kit; medical device; and use to treat a disease or disorder of the central or peripheral nervous system.
EP2252284B1 (en) * 2008-02-06 2011-05-25 Wockhardt Research Centre Pharmaceutical compositions of entacapone, levodopa and carbidopa with improved bioavailability
CN101669925B (en) 2008-09-10 2011-08-10 天津药物研究院 Dry powder inhalation, preparation method and application thereof
WO2010055133A1 (en) 2008-11-14 2010-05-20 Neurosearch A/S Benzimidazole derivatives and their use for modulating the gabaa receptor complex
US20130253056A1 (en) 2009-05-19 2013-09-26 Neuroderm, Ltd. Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same
PT3192500T (en) 2009-05-19 2021-01-05 Neuroderm Ltd Compositions for continuous administration of dopa decarboxylase inhibitors
CN101987081B (en) 2010-07-16 2012-08-08 钟术光 Controlled release preparation
KR101187064B1 (en) 2010-07-18 2012-09-28 주식회사 바이오폴리메드 Cationic lipid, method for manufacturing the same and delivery system comprising the same
US10150792B2 (en) 2010-11-08 2018-12-11 Synthonics, Inc. Bismuth-containing compounds, coordination polymers, methods for modulating pharmacokinetic properties of biologically active agents, and methods for treating patients
TR201808178T4 (en) 2010-11-15 2018-07-23 Neuroderm Ltd Compositions for transdermal delivery of active agents.
SG10201509316SA (en) * 2010-11-15 2015-12-30 Neuroderm Ltd Continuous Administration Of L-Dopa, Dopa Decarboxylase Inhibitors, Catechol-O-Methyl Transferase Inhibitors And Compositions For Same
WO2012079072A2 (en) 2010-12-10 2012-06-14 Synagile Corporation Subcutaneously infusible levodopa prodrug compositions and methods of infusion
WO2013061161A2 (en) 2011-10-28 2013-05-02 Green Bcn Consulting Services Sl New combination therapies for treating neurological disorders
TR201204839A2 (en) * 2012-04-25 2012-12-21 Ali̇ Rai̇f İlaç Sanayi̇ A.Ş. Tablet formulation containing levodopa carbidopa entacapone for prolonged release.
DK2854764T3 (en) 2012-06-05 2019-04-08 Neuroderm Ltd COMPOSITIONS CONTAINING APOMORPHINE AND ORGANIC ACIDS, AND APPLICATIONS THEREOF
US20150217046A1 (en) 2012-06-05 2015-08-06 Synagile Corporation Dosing regimens for subcutaneously infusible acidic compositions
BR112015022390A8 (en) * 2013-03-13 2019-11-26 Neuroderm Ltd use of carbidopa, levodopa and a comt inhibitor for the preparation of a composition for treating parkinson's disease
ES2967693T3 (en) 2014-03-13 2024-05-03 Neuroderm Ltd Dopa decarboxylase inhibitor compositions
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
PT3209302T (en) 2014-10-21 2019-07-19 Abbvie Inc Carbidopa and l-dopa prodrugs and their use to treat parkinson's disease
CN108495617A (en) 2015-11-24 2018-09-04 纽罗德姆有限公司 Including the pharmaceutical composition of levodopa amide and its purposes
WO2018154447A1 (en) 2017-02-21 2018-08-30 Neuroderm Ltd Dopa decarboxylase inhibitor compositions
WO2019038638A1 (en) 2017-08-21 2019-02-28 Neuroderm Ltd Process for preparing purified levodopa amide
WO2019038639A1 (en) 2017-08-21 2019-02-28 Neuroderm Ltd Crystalline levodopa amide free base and methods of making and using same
AR112472A1 (en) 2017-08-21 2019-10-30 Neuroderm Ltd FORM OF LEVODOPA AMIDA CRYSTALLINE SALTS AND METHODS FOR PREPARING AND USING THEM

Also Published As

Publication number Publication date
AU2015228369A1 (en) 2016-10-27
IL247668B (en) 2020-09-30
PT3777833T (en) 2024-01-09
MX2016011837A (en) 2017-04-27
ES2836325T3 (en) 2021-06-24
EP3777833B1 (en) 2023-10-18
CN106413754B (en) 2019-11-29
EP3116475B1 (en) 2020-11-04
HRP20231716T1 (en) 2024-03-15
JP6770158B2 (en) 2020-10-14
ES2967693T3 (en) 2024-05-03
JP2017507973A (en) 2017-03-23
US20190151233A1 (en) 2019-05-23
EP3116475A1 (en) 2017-01-18
FI3777833T3 (en) 2024-01-03
DK3116475T3 (en) 2020-12-07
BR112016021034A2 (en) 2017-08-15
RU2016135952A3 (en) 2018-09-12
US20210038505A1 (en) 2021-02-11
RS65060B1 (en) 2024-02-29
HUE064818T2 (en) 2024-04-28
PL3777833T3 (en) 2024-03-25
US20230240980A1 (en) 2023-08-03
EP3777833A1 (en) 2021-02-17
RU2684105C2 (en) 2019-04-04
PL3116475T3 (en) 2021-02-08
WO2015136538A1 (en) 2015-09-17
EP4299128A2 (en) 2024-01-03
DK3777833T3 (en) 2023-12-18
JP6591995B2 (en) 2019-10-16
US10022320B2 (en) 2018-07-17
EP4299128A3 (en) 2024-04-17
IL247668A0 (en) 2016-11-30
JP2020011977A (en) 2020-01-23
AU2015228369B2 (en) 2020-05-21
HUE052642T2 (en) 2021-05-28
US20150352212A1 (en) 2015-12-10
CA2942244C (en) 2022-08-23
CA2942244A1 (en) 2015-09-17
US10624839B2 (en) 2020-04-21
RU2016135952A (en) 2018-04-13
HRP20201948T1 (en) 2021-01-22
CN106413754A (en) 2017-02-15
PT3116475T (en) 2020-12-15

Similar Documents

Publication Publication Date Title
BR112016021034A8 (en) pharmaceutical composition, use thereof and kit
CL2019000107A1 (en) Arni compositions against plugin component c5 and methods for its use (divisional application 201702014)
PH12017500746B1 (en) Carbidopa and l-dopa prodrugs and their use to treat parkinson's disease
CO2018003168A2 (en) Kras expression modulators
BR112018009235A8 (en) food additive composition
BR112016028845A2 (en) compound, pharmaceutical composition and use of a compound
BR112016019592A8 (en) COMPOUND, USE OF A COMPOUND, AND, PHARMACEUTICAL COMPOSITION
BR112015026238A8 (en) dihydropyrazino-pyrazine compound, pharmaceutical composition comprising it, use of the compound, methods to inhibit or measure phosphorylation and to inhibit protein kinase activity, as well as a kit
BR112015029367A2 (en) combination therapy comprising oxazolidinone-quinolones for use in the treatment of bacterial infections
WO2017184871A9 (en) Carbidopa and l-dopa prodrugs and methods of use
BR112017000312A2 (en) oral health treatment system for the application of amorphous calcium phosphate, use of one or more basic amino acids, composition, and use of one or more amino acids in an oral health treatment system
BR112015019873A2 (en) macrocyclic lrrk2 kinase inhibitors
BR112017022158A2 (en) compounds, pharmaceutical compositions and use of a compound
BR112014000542A2 (en) eosinophilic peroxidase compositions and methods of use thereof
BR112017013674A2 (en) methods and compositions for treating brain diseases.
BR112017014361A2 (en) methods for perfecting cell therapy
BR112014027047A2 (en) new formulation
CL2019001746A1 (en) Aromatic carboxylic acid amides
BR112018009396A2 (en) bacterial composition for use in mitigating performance decline after exercise
AR102778A1 (en) PHARMACEUTICAL COMPOSITION, ITS PREPARATION AND ITS USES
BR112018014723A2 (en) bacterial ghosts for cancer treatment
BR112017014914A2 (en) combined therapy for pulmonary hypertension
AR106313A1 (en) COMBINATION OF LEVODOPA DEUTERATED WITH CARBIDOPA AND OPICAPONE FOR PARKINSON'S DISEASE TREATMENT
UY38472A (en) FOXP3 EXPRESSION MODULATORS
BR112018073396A2 (en) antagonist combination, use of a combination, method for treating cognitive disorders, compound, method for treating alzheimer's disease and pharmaceutical composition

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B350 Update of information on the portal [chapter 15.35 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]